- Home
- BLFS
as 05-30-2025 4:00pm EST
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 1.1B | IPO Year: | 1989 |
| Target Price: | $30.57 | AVG Volume (30 days): | 598.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.70 - $29.55 | Next Earning Date: | 05-08-2025 |
| Revenue: | $87,762,000 | Revenue Growth: | 34.80% |
| Revenue Growth (this year): | 21.21% | Revenue Growth (next year): | 17.59% |
Stock Insider Trading Activity of BioLife Solutions Inc. (BLFS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Aebersold Sarah | BLFS | Chief Human Resources Officer | Apr 9 '25 | Sell | $20.11 | 210 | $4,223.10 | 79,884 | |
| Berard Todd | BLFS | Chief Marketing Officer | Apr 9 '25 | Sell | $20.11 | 324 | $6,515.64 | 135,632 | |
| Foster Karen A. | BLFS | Chief Quality and Operations | Apr 9 '25 | Sell | $20.11 | 286 | $5,751.46 | 195,567 | |
| Mathew Aby J. | BLFS | EVP & Chief Scientific Officer | Apr 9 '25 | Sell | $20.11 | 569 | $11,442.59 | 309,007 | |
| Wichterman Troy | BLFS | Chief Financial Officer | Apr 9 '25 | Sell | $20.11 | 932 | $18,742.52 | 188,310 | |
| Aebersold Sarah | BLFS | Chief Human Resources Officer | Apr 1 '25 | Sell | $22.66 | 5,771 | $130,770.86 | 79,884 | |
| Berard Todd | BLFS | Chief Marketing Officer | Apr 1 '25 | Sell | $22.66 | 8,902 | $201,719.32 | 135,632 | |
| Foster Karen A. | BLFS | Chief Quality and Operations | Apr 1 '25 | Sell | $22.66 | 7,869 | $178,311.54 | 195,567 | |
| Mathew Aby J. | BLFS | EVP & Chief Scientific Officer | Apr 1 '25 | Sell | $22.66 | 10,589 | $239,946.74 | 309,007 | |
| Wichterman Troy | BLFS | Chief Financial Officer | Apr 1 '25 | Sell | $22.66 | 25,687 | $582,067.42 | 188,310 |
Latest BioLife Solutions Inc. News
BLFS Breaking Stock News: Dive into BLFS Ticker-Specific Updates for Smart Investing
Insider Monkey
4 days ago
H.C. Wainwright Maintains Buy rating on BioLife (BLFS) Stock
Medical Device Network
11 days ago
Merit Medical acquires haemostatic device manufacturer Biolife for $120m
Argus Research
11 days ago
BLFS: What does Argus have to say about BLFS?
PR Newswire
18 days ago
BioLife Solutions to Participate in Upcoming Investor Conferences in May and June 2025
Argus Research
18 days ago
BLFS: Raising target price to $24.00
Zacks
19 days ago
Can BioLife Solutions (BLFS) Climb 30.68% to Reach the Level Wall Street Analysts Expect?
Simply Wall St.
22 days ago
BioLife Solutions First Quarter 2025 Earnings: Beats Expectations
GuruFocus.com
23 days ago
BioLife Solutions Inc (BLFS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...
Compare BLFS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BLFS BioLife Solutions Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.